Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)
Authors:
- Valentina GuarneriVGValentina Guarneri
- Antonio FrassoldatiAFAntonio Frassoldati
- Paolo BruzziPBPaolo Bruzzi
- Roberto D'AMicoRDRoberto D'AMico
- Maurizio BelfiglioMBMaurizio Belfiglio
- Annamaria MolinoAMAnnamaria Molino
- Oscar BertettoOBOscar Bertetto
- Stefano CascinuSCStefano Cascinu
- Francesco CognettiFCFrancesco Cognetti
- Angelo Di LeoALAngelo Di Leo
- Paolo PronzatoPPPaolo Pronzato
- Lucio CrinóLCLucio Crinó
- 1 October 2008
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 8 (5) , 453-456
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer TrialJournal of Clinical Oncology, 2008
- Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant TrialJournal of Clinical Oncology, 2007
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialThe Lancet, 2007
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005